Literature DB >> 11568758

Lichenoid drug eruption to salsalate.

M L Powell1, A Ehrlich, D V Belsito.   

Abstract

Cutaneous lichenoid eruptions can arise as a result of exogenous compound exposures. Pharmaceutical drugs, industrial compounds, and inhaled particles have been implicated as causative agents. To date, there have been no recorded cases of lichenoid drug eruptions (LDEs) caused by clinical use of the nonsteroidal anti-inflammatory drug salsalate. We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain. This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication. LDEs can clinically and histologically resemble idiopathic or classic lichen planus. Integrating drug history, clinical morphology, clinical distribution, and histopathology can aid in the differentiation. As in our patient's case, curative treatment for LDE requires discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568758     DOI: 10.1067/mjd.2001.114593

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Prominent alopetic lesions of lichenoid drug eruption treated with topical tacrolimus.

Authors:  Hong Ki Cho; Sung Yul Lee
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

2.  Lichenoid Drug Eruption following Intravenous Application of Orally Formulated Diamorphine, a Semisynthetic Heroin.

Authors:  I Kolm; N Eggmann; J Kamarashev; K Kerl; L E French; G F L Hofbauer
Journal:  Case Rep Dermatol       Date:  2013-06-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.